Company intelligence / Profile preview

Chromatin Bioscience

North Berwick, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Chromatin Bioscience develops and provides synthetic promoter technologies for precise gene regulation, enabling more targeted, safe, and effective cell and gene therapies. Their platform is being integrated in early-stage therapeutic and bioproduction systems, but there are no disclosed clinical results for owned products as of early 2025.

Modalities: Gene therapyCell therapySynthetic biology
Industry: Non-Drug Biotech

Partnerships

JLABS EMEA (Johnson & Johnson Innovation incubator)

Beyond the preview

Go deeper on Chromatin Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromatin Bioscience.

Explore the full profile